Bone Cancer – Pipeline Review, Q2 2011
Bone Cancer – Pipeline Review, Q2 2011
Summary
Global Markets Direct’s, ‘Bone Cancer – Pipeline Review, Q2 2011′, provides an overview of the Bone Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone
Cancer. ‘Bone Cancer – Pipeline Review, Q2 2011′ is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
* A snapshot of the global therapeutic scenario for Bone Cancer.
* A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Bone Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Full Report Details at
- www.fastmr.com/prod/170070_bone_cancer_pipeline_review_q2_2011.a ..
Reasons to buy
* Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Bone Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bone Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Bone Cancer
Bone Cancer Therapeutics under Development by Companies
Bone Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bone Cancer Therapeutics – Products under Development by Companies
Bone Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Bone Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Gilead Sciences, Inc.
Merck & Co., Inc.
Infinity Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
Oncolytics Biotech Inc.
Simcere Pharmaceutical Group
Onyvax Ltd.
ViroStatics, srl
Hawthorn Pharmaceuticals, Inc.
PharmaMar, S.A.
Eleison Pharmaceuticals, Inc.
Epeius Biotechnologies Corporation
Bone Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Xgeva – Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD0530 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPI-926 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin Lipid Complex – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Reolysin – Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRO95780 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onyvax-105 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 717454 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zalypsis – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib mesylate – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bivastin – Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLG201 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMTP-11 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rexin-G – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Liposomal Doxorubicin – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa – Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS1-011 – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Vincristine – Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alimta – Drug Profile
Product Description
Full Table of Contents is available at:
– www.fastmr.com/catalog/product.aspx?productid=170070&dt=t
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world’s top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.